AbbVie Commits US$750 M Upfront to Oncology Collaboration with Genmab

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 6 (Table of Contents)

Published: 22 Jun-2020

DOI: 10.3833/pdr.v2020.i6.2544     ISSN: 1756-7874

Section: Research & Development



In a bid to bolster its oncology portfolio, AbbVie has agreed to partner with Genmab to jointly develop and commercialise three of its clinical-stage antibody programmes: epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details